Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer

Targeting TOR dependence in cancer

(2015)   Oncotarget

mTOR Signalling in Health and Disease: Figure 1

(2011) Christopher G. Proud   BIOCHEMICAL SOCIETY TRANSACTIONS

Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets

(2011) Dong-Mei Li et al.   BREAST CANCER RESEARCH AND TREATMENT

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

(2011) P. Gulhati et al.   CANCER RESEARCH

Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin

(2011) Justin T. Babcock et al.   CURRENT DRUG TARGETS

ATP-Competitive Inhibitors of mTOR: An Update

(2011) S. Schenone et al.   CURRENT MEDICINAL CHEMISTRY

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

(2011) Ruth O'Regan et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

(2011) Ken Inoki et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

(2011) Huanjie Shao et al.   JOURNAL OF HEPATOLOGY

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

Lkb1 and Pten Synergise to Suppress mTOR-Mediated Tumorigenesis and Epithelial-Mesenchymal Transition in the Mouse Bladder

(2011) Boris Y. Shorning et al.   PLoS One

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73

(2010) Su Wei Wong et al.   BREAST CANCER RESEARCH AND TREATMENT

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

(2010) K. Yu et al.   CANCER RESEARCH

mTOR Complex Component Rictor Interacts with PKC  and Regulates Cancer Cell Metastasis

(2010) F. Zhang et al.   CANCER RESEARCH

Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling

(2010) Ming Li et al.   CELLULAR SIGNALLING

Everolimus

(2010) P. J. Houghton   CLINICAL CANCER RESEARCH

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Rapamycin inhibits mTORC1, but not completely

(2009) Carson C. Thoreen et al.   Autophagy

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

(2007) Ahmad Awada et al.   EUROPEAN JOURNAL OF CANCER